US FDA panel rejects Columbia/Watson preterm birth drug
This article was originally published in Scrip
Executive Summary
Concerned that a progesterone gel product Columbia Laboratories and partner Watson Pharmaceuticals are seeking to market as a medicine to prevent preterm births showed no efficacy in US patients in clinical testing, a US FDA advisory panel recommended against approval at a 20 January public meeting.